Vertex's new dilemma: With more positive PhIII data on hand, which of their promising combos should go to the FDA, EMA?
Vertex $VRTX has a pleasant dilemma on its hands.
The big biotech reported that its Phase III trial for a cocktail used to treat cystic fibrosis has come in with positive results for VX-445, tezacaftor and ivacaftor.
In fact, they’re almost identical to the Phase III results they got for VX-659 combined with tezacaftor and ivacaftor. And that means the jury on which triple will head to regulators on both sides of the Atlantic is still out.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
